Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 3:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: B-FREE Clear all
Active, not recruiting Phase 4 Interventional

Accelerated ART Initiation for PWHIV Who Are Out of Care

NCT06374758
View directory record Official record
Conditions
HIV Infections, ART, Noncompliance, Patient
Interventions
The Accelerate model of care, bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg
Other · Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Columbia, Missouri • Kansas City, Missouri • Springfield, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 14, 2026, 3:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)

NCT00983255
View directory record Official record
Conditions
Bacterial Infections
Interventions
TR-701 FA for injection, 200 mg/vial, TR-701 FA tablets
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Sep 14, 2026, 3:32 AM EDT
Active, not recruiting Phase 4 Interventional

Smoking Cessation Program in the Construction Sector

NCT06098144
View directory record Official record
Conditions
Smoking Cessation, Tobacco Use Cessation, Tobacco Smoking
Interventions
Nicorette, Tobacco Quit-line, Brief Behavioral Counseling, Intensive Behavioral Counseling
Drug · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 14, 2026, 3:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025)

NCT06691906
View directory record Official record
Conditions
Healthy
Interventions
Enlicitide decanoate
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Sep 14, 2026, 3:32 AM EDT
Withdrawn Not applicable Interventional

The Brain Ketone Body Challenge Imaging Study

NCT03204604
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Challenge A - low calorie Ensure®, Challenge B - Ensure® plus ketone esters (KE), PET Scan, Cognitive Testing - FCSRT, Story Recall, BVRT, CogState One Card Learning
Dietary Supplement · Procedure · Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 14, 2026, 3:32 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Improving Balance and Energetics of Walking Using a Hip Exoskeleton

NCT05447884
View directory record Official record
Conditions
Stroke
Interventions
A zero impedance mode, controlling a wearable bilateral hip exoskeleton, A personalized optimal assistance mode, controlling a wearable bilateral hip exoskeleton, A free walking mode, without wearing a wearable bilateral hip exoskeleton
Other
Lead sponsor
North Carolina State University
Other
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 14, 2026, 3:32 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Collection of Samples USOPTIVAL Study

NCT04792684
View directory record Official record
Conditions
Colorectal Cancer (CRC), Advanced Adenomas (AA)
Interventions
Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel
Diagnostic Test
Lead sponsor
Universal Diagnostics
Industry
Eligibility
45 Years to 84 Years
Enrollment
1,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
16
States / cities
Chula Vista, California • San Diego, California • Walnut Creek, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 14, 2026, 3:32 AM EDT
Terminated Phase 3 Interventional Results available

Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy

NCT01077518
View directory record Official record
Conditions
Lymphoma, Follicular
Interventions
Ofatumumab, Bendamustine infusion, Ofatumumab and Bendamustine infusions (Arm A), Bendamustine infusion (Arm B)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
18
States / cities
Tucson, Arizona • Beverly Hills, California • Palm Springs, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Sep 14, 2026, 3:32 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

NCT06284460
View directory record Official record
Conditions
Pathway Mutant Myelodysplastic Syndromes, Myelodysplastic Neoplasm, Myeloproliferative Neoplasm
Interventions
ASTX029, ASTX727
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 14, 2026, 3:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers

NCT01500408
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Interferon beta-1a (current approved manufacturing process invloving FBS), Interferon beta-1a (new process, manufactured without FBS)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 18, 2012 · Synced Sep 14, 2026, 3:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cortisol Regulation in Polycystic Ovary Syndrome (PCOS)

NCT00694759
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
pioglitazone, metformin, placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 8, 2019 · Synced Sep 14, 2026, 3:32 AM EDT
Terminated Phase 2 Interventional Results available

Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)

NCT04409873
View directory record Official record
Conditions
COVID-19, SARS-CoV 2, Severe Acute Respiratory Syndrome Coronavirus 2, Virus Disease, Coronavirus Infections, Pharyngeal Diseases
Interventions
Oral-B Mouth Sore mouthwash, Crest Pro-Health Multi-Protection mouthwash, CloSYS Ultra Sensitive Rinse mouthwash, Distilled water, Listerine Zero Mouthwash Product
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 14, 2026, 3:32 AM EDT
Terminated Phase 2 Interventional

Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

NCT01425970
View directory record Official record
Conditions
Hepatitis C
Interventions
INX-08189, Placebo matching with INX-08189, Pegylated interferon alfa-2a, Ribavirin, Daclatasvir
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Anaheim, California • La Jolla, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Sep 14, 2026, 3:32 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT00474188
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
CC-5013 (lenalidomide), dexamethasone
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Glendale, Arizona • Beverly Hills, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2009 · Synced Sep 14, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Efficacy of 10% Arginine Bicarbonate Prophylaxis Paste

NCT01072188
View directory record Official record
Conditions
Hypersensitivity
Interventions
Arginine/Calcium Carbonate, Nupro - Fluoride Free
Device
Lead sponsor
Colgate Palmolive
Industry
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Langhorne, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Sep 14, 2026, 3:32 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study on Functional Electrical Stimulation (FES) Cycling Following Spinal Cord Injury

NCT01217047
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
FES Cycling, Cycling without FES, Lumbar puncture, Mood assessment
Device · Procedure · Behavioral
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 14, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine

NCT03207750
View directory record Official record
Conditions
Rotavirus Infection, Rotavirus Vaccines
Interventions
Rotarix, Pediarix, Hiberix, Prevenar 13
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
47
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Sep 14, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

NCT03823300
View directory record Official record
Conditions
Wet Macular Degeneration
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
41
States / cities
Phoenix, Arizona • Mountain View, California • Sacramento, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Sep 14, 2026, 3:32 AM EDT
Completed No phase listed Observational

Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag Test

NCT04557046
View directory record Official record
Conditions
Covid19
Interventions
Nasal Swab, Nasopharyngeal swab, Throat swab, Fingerstick, Saliva specimen
Diagnostic Test
Lead sponsor
LumiraDx UK Limited
Industry
Eligibility
Not listed
Enrollment
1,134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
7
States / cities
Altamonte Springs, Florida • Kissimmee, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 14, 2026, 3:32 AM EDT
Terminated Phase 2 Interventional Results available

A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma

NCT02811679
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
Blinatumomab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 14, 2026, 3:32 AM EDT
Completed Not applicable Interventional Results available

WeChat Quit Coach Pilot Study

NCT05130788
View directory record Official record
Conditions
Smoking Cessation
Interventions
WeChat Quit Coach, Leaflet, Optional Nicotine Replacement Therapy (NRT) Patches or Lozenges
Behavioral · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 14, 2026, 3:32 AM EDT
Completed Not applicable Interventional

A Test of Different Degrees of Cost Sharing on Program Uptake and Attendance

NCT01756066
View directory record Official record
Conditions
Obesity
Interventions
Different levels of cost sharing
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
1,239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Davidson, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 20, 2015 · Synced Sep 14, 2026, 3:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome

NCT04977388
View directory record Official record
Conditions
Menkes Disease, Occipital Horn Syndrome
Interventions
Droxidopa, Placebo
Drug · Other
Lead sponsor
Stephen G. Kaler, MD
Other
Eligibility
18 Years to 50 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 14, 2026, 3:32 AM EDT
Recruiting Phase 2 Interventional

Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy

NCT04476901
View directory record Official record
Conditions
Non-ischemic Dilated Cardiomyopathy
Interventions
allogeneic human mesenchymal stem cells (hMSCs), Placebo
Biological · Other
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Stanford, California • Miami, Florida • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 14, 2026, 3:32 AM EDT